A phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MBX-102 in combination with allopurinol in gout patients with an inadequate hypouricemic response to allopurinol alone

Trial Profile

A phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MBX-102 in combination with allopurinol in gout patients with an inadequate hypouricemic response to allopurinol alone

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Arhalofenate (Primary) ; Allopurinol
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 01 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top